4G/5G variant of plasminogen activator inhibitor-1 gene and severe pregnancy-induced hypertension: Subgroup analyses of variants of angiotensinogen and endothelial nitric oxide synthase

Journal of Epidemiology

Volumn 19, Issue 6, 2009, Pages 275-280

  Kobashi, Gen ^a,b   Ohta, Kaori ^a,b,c   Yamada, Hideto ^b   Hata, Akira ^c   Minakami, Hisanori ^b   Sakuragi, Noriaki ^b   Tamashiro, Hiko ^b   Fujimoto, Seiichiro ^d  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Sapporo Maternity Women's Hospital   (Japan)

Author keywords

Angiotensinogen; Endothelial nitric oxide synthase; Gene polymorphism; Plasminogen activator inhibitor 1; Pregnancy induced hypertension

Indexed keywords

ANGIOTENSINOGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; FEMALE; GENETICS; GENOTYPE; HUMAN; MATERNAL HYPERTENSION; PREGNANCY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANGIOTENSINOGEN; FEMALE; GENOTYPE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; NITRIC OXIDE SYNTHASE TYPE III; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY;

EID: 74249115384     PISSN: 09175040     EISSN: 13499092     Source Type: Journal    
DOI: 10.2188/jea.JE20090003     Document Type: Article

References (39)

1. Taylor DJ. The epidemiology of hypertension during pregnancy. In: Rubin PC, editor. Handbook of hypertension. Vol. 10. Hypertension in pregnancy. Amsterdam: Elisevier. 1988; p. 223-40.
2. de Groot CJ, Taylor RN. New insights into the etiology of pre-eclampsia. Ann Med. 1993;25:243-9.
3. GOPEC Consortium. Disentangling fetal and maternal susceptibility for pre-eclampsia: a British multicenter candidate-gene study. Am J Hum Genet. 2005;77:127-31.
4. Oudejans CB, van Dijk M, Oosterkamp M, Lachmeijer A, Blankenstein MA. Genetics of preeclampsia: paradigm shifts. Hum Genet. 2007;120:607-12.
5. Mohaupt M. Molecular aspects of preeclampsia. Mol Aspects Med. 2007;28:169-91.
6. Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, van Zonneveld AJ, et al. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J. 1986;5:2539-44.
7. Reith A, Booth NA, Moore NR, Cruickshank DJ, Bennett B. Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, pre-eclampsia and hydatidiform mole. Br J Obstet Gynaecol. 1993;100:370-4.
8. Caron C, Goudemand J, Marey A, Beague D, Ducroux G, Drouvin F. Are haemostatic and brinolytic parameters predictors of preeclampsia in pregnancy-associated hypertension? Thromb Haemost. 1991;66:410-4.
9. Estelles A, Gilabert J, Keeton M, Eguchi Y, Aznar J, Grancha S, et al. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood. 1994;84:143-50.
10. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost. 1995;74:837-41.
11. Kathiresan S, Gabriel SB, Yang Q, Lochner AL, Larson MG, Levy D, et al. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation. 2005;112:1728-35.
12. Yamada N, Arinami T, Yamakawa-Kobayashi K, Watanabe H, Sohda S, Hamada H, et al. The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia. J Hum Genet. 2000;45:138-41.
13. Hakli T, Romppanen EL, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S. Plasminogen activator inhibitor-1 polymorphism in women with pre-eclampsia. Genet Test. 2003;7:265-8.
14. Ward K, Hata A, Jeunemaitre X, Helin C, Nelson L, Namikawa C, et al. A molecular variant of angiotensinogen associated with preeclampsia. Nat Genet. 1993;4:59-61.
15. Kobashi G, Hata A, Shido K, Kato EH, Yamada H, Fujimoto S, et al. Association of a variant of the angiotensinogen gene with pure type of hypertension in pregnancy in the Japanese: implication of a racial difference and signicance of an age factor. Am J Med Genet. 1999;86:232-6.
16. Yoshimura T, Yoshimura M, Tabata A, Shimasaki Y, Nakayama M, Miyamoto Y, et al. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with severe preeclampsia. J Soc Gynecol Investig. 2000;7:238-41.
17. Kobashi G, Yamada H, Ohta K, Kato E, Ebina Y, Fujimoto S. Endothelial nitric oxide synthase gene (NOS3) variant and hypertension in pregnancy. Am J Med Genet. 2001;103:241-4.
18. Serrano NC, Casas JP, Díaz LA, Páez C, Mesa CM, Cifuentes R, et al. Endothelial NO synthase genotype and risk of preeclampsia: a multicenter case-control study. Hypertension. 2004;44:702-7.
19. Landau R, Xie HG, Dishy V, Wood AJ, Stein CM, Smiley RM. No association of the Asp298 variant of the endothelial nitric oxide synthase gene with preeclampsia. Am J Hypertens. 2004;17:391-4.
20. Yoshimura T, Chowdhury FA, Yoshimura M, Okamura H. Genetic and environmental contributions to severe preeclampsia: lack of association with the endothelial nitric oxide synthase Glu298Asp variant in a developing country. Gynecol Obstet Invest. 2003;56:10-3.
21. National High Blood Pressure Education Program Working Group. Report on high blood pressure in pregnancy. Am J Obstet Gynecol. 1990;163:1691-712.
22. Russ AP, Maerz W, Ruzicka V, Stein U, Gross W. Rapid detection of the hypertension-associated Met235 → Thr allales of the human angiotensinogen gene. Hum Mol Genet. 1993;2:609-10.
23. Shimasaki Y, Yasue H, Yoshimura M, Nakayama M, Kugiyama K, Ogawa H, et al. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol. 1998;31:1506-10.
24. Matsubara Y, Murata M, Isshiki I, Watanabe R, Zama T, Watanabe G, et al. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels. Int J Hematol. 1999;69:43-7.
25. Oudejans CB, van Dijk M, Oosterkamp M, Lackmeijer A, Blankenstein MA. Genetics of preeclampsia: paradigm shifts. Hum Genet. 2007;120:607-12.
26. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest. 1997;99:1786-97.
27. Morgan T, Craven C, Lalouel JM, Ward K. Angiotensinogen Thr235 variant is associated with abnormal physiologic change of the uterine spiral arteries in rst-trimester decidua. Am J Obstet Gynecol. 1999;180:95-102.
28. Kobashi G, Hata A, Shido K, Ohta K, Yamada H, Fujimoto S, et al. The M235T variant of the angiotensinogen gene and the body mass index are useful markers for prevention of hypertension in pregnancy: a tree-based analysis of gene-environment interaction. Semin Thromb Hemost. 2002;28:501-6.
29. Philip I, Plantefeve G, Vuillaumier-Barrot S, Vicaut E, LeMarie C, Henrion D, et al. G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine. Circulation. 1999;99:3096-8.
30. Ohta K, Kobashi G, Hata A, Yamada H, Minakami H, Fujimoto S, et al. Association between a variant of the glutathione S-transferase P1 gene (GSTP1) and hypertension in pregnancy in Japanese: interaction with parity, age, and genetic factors. Semin Thromb Hemost. 2003;29:653-9.
31. Katoh M, Egashira K, Mitsui T, Chishima S, Takeshita A, Narita H. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. J Mol Cell Cardiol. 2000;32:73-83.
32. Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deciency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation. 2001;104:839-44.
33. Kato N, Sugiyama T, Morita H, Kurihara H, Furukawa T, Isshiki T, et al. Comprehensive analysis of the renin-angiotensin gene polymorphisms with relation to hypertension in the Japanese. J Hypertens. 2000;18:1025-32.
34. Rodriguez-Perez JC, Rodriguez-Esparragon FJ, Hernandez-Perera O, Fiuza-Perez MD, Anabitarte-Prieto A, Losada-Cabrera A. Effects of the angiotensinogen gene M235T and A(-6)G variants on blood pressure and other vascular risk factors in a Spanish population. J Hum Hypertens. 2000;14:789-93.
35. Lachmeijer AM, Dekker GA, Pals G, Aarnoudse JG, ten Kate LP, Arngrimsson R. Searching for preeclampsia genes: the current position. Eur J Obstet Gynecol Reprod Biol. 2002;105:94-113.
36. Mondry A, Loh M, Liu P, Zhu AL, Nagel M. Polymorphisms of the insertion/deletion ACE and M235T AGT genes and hypertension: surprising new ndings and meta-analysis of data. BMC Nephrol. 2005;6:1.
37. Heltianu C, Costache G, Gafencu A, Diaconu M, Bodeanu M, Cristea C, et al. Relationship of eNOS gene variants to diseases that have in common an endothelial cell dysfunction. J Cell Mol Med. 2005;9:135-42.
38. Spoto B, Benedetto FA, Testa A, Tripepi G, Mallamaci F, Maas R, et al. Atherosclerosis and the Glu298Asp polymorphism of the eNOS gene in white patients with end-stage renal disease. Am J Hypertens. 2005;18:1549-55.
39. Sandrim VC, Coelho EB, Nobre F, Arado GM, Lanchote VL, Tanus-Santos JE. Susceptible and protective eNOS haplotypes in hypertensive black and white subjects. Atherosclerosis. 2006;186:428-32.